ZA202107235B - Compositions and methods for treating ocular disease - Google Patents
Compositions and methods for treating ocular diseaseInfo
- Publication number
- ZA202107235B ZA202107235B ZA2021/07235A ZA202107235A ZA202107235B ZA 202107235 B ZA202107235 B ZA 202107235B ZA 2021/07235 A ZA2021/07235 A ZA 2021/07235A ZA 202107235 A ZA202107235 A ZA 202107235A ZA 202107235 B ZA202107235 B ZA 202107235B
- Authority
- ZA
- South Africa
- Prior art keywords
- compositions
- methods
- ocular disease
- treating ocular
- treating
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824017P | 2019-03-26 | 2019-03-26 | |
| PCT/US2020/024972 WO2020198481A1 (en) | 2019-03-26 | 2020-03-26 | Compositions and methods for treating ocular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202107235B true ZA202107235B (en) | 2023-10-25 |
Family
ID=72609544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/07235A ZA202107235B (en) | 2019-03-26 | 2021-09-27 | Compositions and methods for treating ocular disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12540171B2 (https=) |
| EP (1) | EP3946418A4 (https=) |
| JP (1) | JP7650074B2 (https=) |
| KR (1) | KR20210146352A (https=) |
| CN (1) | CN113710264A (https=) |
| AU (1) | AU2020248438A1 (https=) |
| CA (1) | CA3134816A1 (https=) |
| EA (1) | EA202192607A1 (https=) |
| IL (1) | IL286625A (https=) |
| MX (1) | MX2021011727A (https=) |
| WO (1) | WO2020198481A1 (https=) |
| ZA (1) | ZA202107235B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2015781A4 (en) * | 2005-09-12 | 2009-12-23 | Univ Johns Hopkins | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF |
| EP2649095B1 (en) * | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| CN108883150A (zh) | 2015-11-19 | 2018-11-23 | 阿斯克雷佩西治疗公司 | 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂 |
| MX2019003895A (es) * | 2016-10-04 | 2019-10-07 | Asclepix Therapeutics Inc | Compuestos y metodos para activar la señalizacion tie2. |
| US20200179285A1 (en) * | 2017-05-08 | 2020-06-11 | The Johns Hopkins University | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| EP3661536A4 (en) * | 2017-08-03 | 2021-07-21 | Asclepix Therapeutics, Inc. | PROCESS FOR IDENTIFICATION AND MANUFACTURING OF PHARMACEUTICAL INGREDIENTS FOR ACTIVATING A TIE2 RECEPTOR |
-
2020
- 2020-03-26 CN CN202080030026.4A patent/CN113710264A/zh active Pending
- 2020-03-26 KR KR1020217034683A patent/KR20210146352A/ko active Pending
- 2020-03-26 EP EP20776493.7A patent/EP3946418A4/en active Pending
- 2020-03-26 US US17/442,682 patent/US12540171B2/en active Active
- 2020-03-26 WO PCT/US2020/024972 patent/WO2020198481A1/en not_active Ceased
- 2020-03-26 AU AU2020248438A patent/AU2020248438A1/en active Pending
- 2020-03-26 JP JP2021557369A patent/JP7650074B2/ja active Active
- 2020-03-26 EA EA202192607A patent/EA202192607A1/ru unknown
- 2020-03-26 MX MX2021011727A patent/MX2021011727A/es unknown
- 2020-03-26 CA CA3134816A patent/CA3134816A1/en active Pending
-
2021
- 2021-09-23 IL IL286625A patent/IL286625A/en unknown
- 2021-09-27 ZA ZA2021/07235A patent/ZA202107235B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210146352A (ko) | 2021-12-03 |
| AU2020248438A1 (en) | 2021-10-28 |
| WO2020198481A1 (en) | 2020-10-01 |
| CA3134816A1 (en) | 2020-10-01 |
| EP3946418A4 (en) | 2023-02-22 |
| US12540171B2 (en) | 2026-02-03 |
| JP7650074B2 (ja) | 2025-03-24 |
| EA202192607A1 (ru) | 2022-03-03 |
| US20230054032A1 (en) | 2023-02-23 |
| CN113710264A (zh) | 2021-11-26 |
| IL286625A (en) | 2021-12-01 |
| MX2021011727A (es) | 2022-01-24 |
| JP2022527276A (ja) | 2022-06-01 |
| EP3946418A1 (en) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| IL277333A (en) | Methods for treating eye diseases | |
| EP3880809A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF WILSON'S DISEASE | |
| IL284344A (en) | Pharmaceutical preparations for the eyes and methods for the treatment of diseases of the surface of the eye | |
| IL277182A (en) | Compositions and methods for treating Parkinson's disease | |
| PT3861985T (pt) | Composições e métodos para tratar doenças oculares | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| ZA202002991B (en) | Methods and compositions for assessing and treating intraocular diseases and disorders | |
| SMT202500382T1 (it) | Composizioni per trattare e/o prevenire malattie da aggregazione proteica | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| IL275985A (en) | Preparations and methods for the treatment of retinal disorders | |
| IL287802A (en) | Preparations and methods for the treatment of eye diseases | |
| IL287831A (en) | Oxymetazoline compounds and methods for treating eye diseases | |
| ZA202205289B (en) | Compositions and methods for treating liver disease | |
| ZA202107235B (en) | Compositions and methods for treating ocular disease | |
| EP3691654A4 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES | |
| EP3634438A4 (en) | COMPOSITIONS FOR THE TREATMENT OF NETWORK DISEASES AND METHOD FOR THEIR MANUFACTURE AND USE | |
| EP3618850A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE PATHOLOGIES | |
| IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
| EP3768095A4 (en) | Compositions and methods for treating diarrheal diseases | |
| ZA202007183B (en) | Compositions and methods for treating the eye | |
| ZA202101360B (en) | Compositions and methods for treating the eye | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| IL286083A (en) | Compositions and methods for treating Huntington's disease | |
| EP3993833A4 (en) | Compositions and methods for treating eye diseases |